



*cancers*



an Open Access Journal by MDPI

## Advances in the Treatment of Renal Cell Carcinoma

Guest Editors:

**Dr. Paul Reynolds**

School of Medicine, University of  
St Andrews, Medical and  
Biological Sciences Building,  
North Haugh, St Andrews KY16  
9TF, UK

**Mr. Grant D Stewart**

Department of Surgery,  
University of Cambridge,  
Cambridge, CB2 0QQ, UK

Deadline for manuscript  
submissions:

**closed (30 September 2020)**

### Message from the Guest Editors

Renal cell carcinoma (RCC) represents 90% of kidney cancers and around 3% of all malignancies worldwide. Established risk factors for RCC include increasing age, smoking, obesity, and hypertension. The incidence of RCC is rising, partly due to changes in the above risk factors and partly due to the increased detection of asymptomatic RCC by the widespread use of modern abdominal imaging techniques. While there has been a decrease in the number of patients presenting with advanced metastatic RCC, compared to early disease presentation, there remains the significant issue of clinical resistance to current therapies and drug resistance remains a significant health burden.

This Special Issue will focus on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon. We look forward to your contributions.



[mdpi.com/si/35079](https://mdpi.com/si/35079)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI